The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease

INTRODUCTION: The increasing financial burden associated with diabetes treatment presents a challenge to healthcare systems worldwide. Recently, clinical guidelines have focussed on patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD) and recommend a sodium-glucose co-tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Ehlers, Lars Holger, Lamotte, Mark, Monteiro, Sofia, Sandgaard, Susanne, Holmgaard, Pia, Frary, Evan C., Ejskjaer, Niels
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099952/
https://www.ncbi.nlm.nih.gov/pubmed/33856655
http://dx.doi.org/10.1007/s13300-021-01040-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099952/
https://www.ncbi.nlm.nih.gov/pubmed/33856655
http://dx.doi.org/10.1007/s13300-021-01040-y

Ejemplares similares